These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

2093 related articles for article (PubMed ID: 33924827)

  • 1. Nephrotoxicity as a Complication of Chemotherapy and Immunotherapy in the Treatment of Colorectal Cancer, Melanoma and Non-Small Cell Lung Cancer.
    Jagieła J; Bartnicki P; Rysz J
    Int J Mol Sci; 2021 Apr; 22(9):. PubMed ID: 33924827
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Nephrological Detrimental Impacts Resulting From Novel Immunotherapy Drugs Used in the Treatment of Cancer: A Systematic Review.
    Jaiswal A; Shergill K; Boppana K; Almansouri NE; Bakkannavar S; Faheem Y; Nath TS
    Cureus; 2024 Feb; 16(2):e54487. PubMed ID: 38516472
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Renal complications of cancer therapies.
    Schanz M; Schricker S; Pfister F; Alscher MD; Kimmel M
    Drugs Today (Barc); 2018 Sep; 54(9):561-575. PubMed ID: 30303496
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacovigilance Assessment of Immune-Mediated Reactions Reported for Checkpoint Inhibitor Cancer Immunotherapies.
    Ali AK; Watson DE
    Pharmacotherapy; 2017 Nov; 37(11):1383-1390. PubMed ID: 28950039
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinicopathological features of acute kidney injury associated with immune checkpoint inhibitors.
    Cortazar FB; Marrone KA; Troxell ML; Ralto KM; Hoenig MP; Brahmer JR; Le DT; Lipson EJ; Glezerman IG; Wolchok J; Cornell LD; Feldman P; Stokes MB; Zapata SA; Hodi FS; Ott PA; Yamashita M; Leaf DE
    Kidney Int; 2016 Sep; 90(3):638-47. PubMed ID: 27282937
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Acute interstitial nephritis after sequential ipilumumab - nivolumab therapy of metastatic melanoma.
    Bottlaender L; Breton AL; de Laforcade L; Dijoud F; Thomas L; Dalle S
    J Immunother Cancer; 2017 Jul; 5(1):57. PubMed ID: 28716106
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinicopathological spectrum of kidney diseases in cancer patients treated with vascular endothelial growth factor inhibitors: a report of 5 cases and review of literature.
    Usui J; Glezerman IG; Salvatore SP; Chandran CB; Flombaum CD; Seshan SV
    Hum Pathol; 2014 Sep; 45(9):1918-27. PubMed ID: 25087655
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The link between kidney disease and cancer: complications and treatment.
    Malyszko J; Tesarova P; Capasso G; Capasso A
    Lancet; 2020 Jul; 396(10246):277-287. PubMed ID: 32711803
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Kidney Complications of Immune Checkpoint Inhibitors: A Review.
    Shingarev R; Glezerman IG
    Am J Kidney Dis; 2019 Oct; 74(4):529-537. PubMed ID: 31303350
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Nephrotoxicity associated with anticancer agents: perspective on onconephrology from nephrologists.
    Matsubara T; Yokoi H; Yamada H; Yanagita M
    Int J Clin Oncol; 2023 May; 28(5):625-636. PubMed ID: 36872414
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Long-term renal follow-up of children treated with cisplatin, carboplatin, or ifosfamide: a pilot study.
    McMahon KR; Harel-Sterling M; Pizzi M; Huynh L; Hessey E; Zappitelli M
    Pediatr Nephrol; 2018 Dec; 33(12):2311-2320. PubMed ID: 30218190
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tubulointerstitial injury associated with chemotherapeutic agents.
    Shirali AC; Perazella MA
    Adv Chronic Kidney Dis; 2014 Jan; 21(1):56-63. PubMed ID: 24359987
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Onco-nephrology: renal toxicities of chemotherapeutic agents.
    Perazella MA
    Clin J Am Soc Nephrol; 2012 Oct; 7(10):1713-21. PubMed ID: 22879440
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Immune check point inhibitor-associated renal toxicity].
    Izzedine H; Gueutin V
    Nephrol Ther; 2020 Feb; 16(1):19-26. PubMed ID: 31843355
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Nephrotoxicity of anticancer treatment.
    Malyszko J; Kozlowska K; Kozlowski L; Malyszko J
    Nephrol Dial Transplant; 2017 Jun; 32(6):924-936. PubMed ID: 28339935
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Nephrotoxicity induced by chemotherapy].
    Di Vito R; Sirolli V; Amoroso L; Bonomini M
    G Ital Nefrol; 2011; 28(3):296-304. PubMed ID: 21626498
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Nephrotoxicity Associated with Novel Anticancer Agents (Aflibercept, Dasatinib, Nivolumab): Case Series and Nephrological Considerations.
    Piscitani L; Sirolli V; Di Liberato L; Morroni M; Bonomini M
    Int J Mol Sci; 2020 Jul; 21(14):. PubMed ID: 32664269
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Response to combined ipilimumab and nivolumab after development of a nephrotic syndrome related to PD-1 monotherapy.
    Glutsch V; Grän F; Weber J; Gesierich A; Goebeler M; Schilling B
    J Immunother Cancer; 2019 Jul; 7(1):181. PubMed ID: 31300044
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Erlotinib: CP 358774, NSC 718781, OSI 774, R 1415.
    Adis International Ltd
    Drugs R D; 2003; 4(4):243-8. PubMed ID: 12848590
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Use of Immunotherapy in Extensive-Stage Small Cell Lung Cancer.
    Konala VM; Madhira BR; Ashraf S; Graziano S
    Oncology; 2020; 98(11):749-754. PubMed ID: 32663833
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 105.